Today: 21 May 2026
Browse Category

NYSE:JNJ 24 December 2025 - 5 January 2026

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson shares closed up 0.02% at $206.95 on Wednesday, ahead of the New Year’s Day market holiday. The company completed its $3.05 billion acquisition of Halda Therapeutics and plans to appeal a $1.5 billion talc verdict. Drugmakers are set to raise list prices on at least 350 medicines in 2026, Reuters reported. J&J’s fourth-quarter earnings call is set for Jan. 21.
1 January 2026
·
Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson closed its $3.05 billion acquisition of Halda Therapeutics, saying the deal will cut adjusted EPS by $0.20 between late 2025 and 2026. JNJ shares edged up 0.02% to $206.95 as the S&P 500 fell 0.74% on the year’s final trading day. Barclays raised its price target to $217, maintaining an Equal Weight rating. The company will discuss its 2026 outlook on Jan. 21.
1 January 2026
··
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, adding the RIPTAC oncology platform and lead prostate cancer program. Shares slipped 0.3% to $206.91 in after-hours trading. The company expects about $0.20 dilution to adjusted EPS, split between 2025 and 2026, and will discuss 2026 guidance on its Jan. 21 earnings call.
31 December 2025
··
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, a cancer drug developer, on Monday. The company said it expects about $0.20 in adjusted EPS dilution, split between the fourth quarter and 2026. JNJ shares ended down 0.02% at $207.56. Investors await the Jan. 21 earnings call for 2026 guidance.
30 December 2025
····
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson has halted a Phase 2b trial of its experimental eczema drug JNJ-5939 after interim results failed to meet efficacy targets, though the therapy was well tolerated. The stock last traded near $207.63, slightly down before the market closed for the weekend. The New York Stock Exchange will reopen Monday.
28 December 2025
··
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson shares closed at $207.63 Friday, down 0.07%, after the company halted a mid-stage trial of its eczema drug JNJ-5939 due to lack of efficacy. The drug was well-tolerated but failed to meet targets in interim analysis. JNJ’s market cap stands near $500 billion, with a 2.5% dividend yield. The stock traded at $207.86 after hours ahead of Monday’s market open.
27 December 2025
··
Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

U.S. stock markets were closed Saturday after Wall Street ended Friday nearly flat; the Dow slipped 0.04%, S&P 500 fell 0.03%, and Nasdaq lost 0.09%. Large-cap healthcare stocks held steady, while biotech lagged. Johnson & Johnson halted a Phase 2 eczema drug trial after missing efficacy goals. Healthcare ETFs closed Friday with XLV at $156.05, XBI at $124.98, and IBB at $171.44.
27 December 2025
Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

U.S. markets reopen Friday, Dec. 26, after the Christmas holiday. Johnson & Johnson shares last traded near $207.78, up 0.6% from the previous close, with recent sessions marked by low volume. The company faces renewed legal pressure after a Baltimore jury ordered it to pay over $1.5 billion in a talc case, with J&J planning to appeal. Over 67,000 talc-related lawsuits remain unresolved.
26 December 2025
·
Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson shares last closed at $207.78 on Dec. 24, up 0.97%, with after-hours trading nearly flat at $207.75 ahead of the Christmas market closure. The New York Stock Exchange was shut Dec. 25 and will reopen Dec. 26. J&J faces ongoing headline risk from talc litigation, including a recent $1.5 billion jury verdict in Baltimore. The company is appealing and disputes the claims.
25 December 2025
·
Johnson & Johnson Stock After the Bell Dec. 24, 2025: JNJ Holds Near $208 — Key News, Forecasts, and What to Watch Before the Next Market Open

Johnson & Johnson Stock After the Bell Dec. 24, 2025: JNJ Holds Near $208 — Key News, Forecasts, and What to Watch Before the Next Market Open

Johnson & Johnson shares closed up 0.95% at $207.78 in a shortened Christmas Eve session, with trading volume at 2.38 million shares. The move comes as a Baltimore jury ordered J&J to pay over $1.5 billion in a talc cancer case, which the company plans to appeal. U.S. markets closed early and will remain shut for Christmas Day.
24 December 2025
··
1 … 3 4 5 6 7 8

Stock Market Today

  • Planet Labs Nears Sustainable Profitability Amid Industry Challenges
    May 21, 2026, 3:12 PM EDT. Planet Labs (PL) operates a vast network of Earth observation satellites capturing global images daily. Despite technological advances and expanded roles in defense and agriculture, the company has yet to secure steady profits due to high costs in satellite manufacturing, launches, maintenance, and R&D. Revenue growth lags behind fixed costs, while long government sales cycles delay cash flow. Management's 2026 guidance shows optimism, focusing on cost control, vertical specialization, and software monetization to enhance margins. Industry peers Rocket Lab (RKLB) and BlackSky Technology (BKSY) face similar profitability challenges. PL's stock has surged 117% year-to-date but trades at a lofty price-to-sales ratio of 31.38, far above the industry average of 3.86, reflecting high investor expectations amid ongoing financial pressures.

Latest articles

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

21 May 2026
Nebius Group N.V. shares surged 15.6% to $221.72 after announcing a fuel cell power deal with Bloom Energy, securing up to 328 MW of on-site electricity capacity for its AI infrastructure. The agreement could cost Nebius up to $2.6 billion over 10 years. Bloom shares rose 12.2% on the news. Nebius's first-quarter revenue jumped to $399 million from $50.9 million a year earlier.
Sirius XM stock nears new highs as traders look at audio strategy

Sirius XM stock nears new highs as traders look at audio strategy

21 May 2026
Sirius XM shares rose 6.8% to $28.90 by 2:07 p.m. EDT Thursday, outpacing major U.S. indexes. The rally followed CFO Zac Coughlin’s investor conference appearance and news of a renewed multi-year NASCAR broadcast deal. First-quarter subscriber losses were smaller than expected, and revenue topped forecasts. Volume reached 4.8 million shares, with a market value near $9.8 billion.
KEEL Surges as Investors Back Keel’s AI Data Center Plans

KEEL Surges as Investors Back Keel’s AI Data Center Plans

21 May 2026
Keel Infrastructure shares jumped 7.1% to $4.53 Thursday, nearing a 52-week high, as investors bet on its pivot from crypto mining to AI-focused power infrastructure. Trading volume reached 22.31 million shares, below average. The company reported a wider net loss of $145.35 million for the March quarter on lower revenue and warned its transformation faces risks tied to permits, costs, and competition.
Go toTop